Heron Therapeutics Soars 13.74% on Insider Buying, Strategic Moves

On August 13, 2025, Heron Therapeutics experienced a significant surge in its stock price, rising by 13.74% in pre-market trading. This notable increase can be attributed to several key developments and strategic moves by the company.

Heron Therapeutics has recently seen substantial insider buying, with Rubric Capital Management LP acquiring 2,387,225 shares at $1.50 per share, and Director Adam Morgan purchasing 1,766,546 shares for approximately $2.65 million, increasing his ownership by 25.28% to nearly 8.75 million shares. These transactions reflect a strong confidence in the company's future prospects among its key stakeholders.

The company has also strengthened its financial position through a series of strategic financing moves. Heron issued $35 million in new senior unsecured convertible notes due 2031 for $33.25 million and completed a private placement of 13,225,227 shares of common stock. These actions have enhanced the company's financial flexibility and positioned it to accelerate its strategic initiatives.

Heron Therapeutics has made significant progress in its operational and financial performance. The company reported strong demand growth for its products ZYNRELEF and APONVIE, which has outpaced net revenue growth over the past two quarters. Additionally, the transition from a C-code to a permanent J-code for ZYNRELEF, effective October 1, is expected to streamline reimbursement processes and reduce administrative burden, ultimately supporting broader adoption and better patient outcomes.

During the second quarter earnings call, Heron Therapeutics reported a net loss of $2.4 million, compared to a net loss of $9.2 million for the same period in 2024. The company's adjusted EBITDA for the first half of 2025 was $7.9 million, reflecting its continued focus on disciplined execution and operational efficiency. Heron Therapeutics has maintained its net revenue guidance of $153 million to $163 million and revised its adjusted EBITDA guidance to a range of $9 million to $13 million for the year.